SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1390)8/4/2000 4:35:27 PM
From: nigel bates  Read Replies (1) of 52153
 
"The R&D expense ultimately has to flow through to the income statement at some point or another. The issue is whether it should flow through when you first spend the money (as it does now), or over some longer period (here the life of the drug)."

Yes but how could one reasonably forecast the life of the drug these days. The pace of development is now such that the lifetime of a drug, even if approved, must be highly uncertain.
I would prefer to retain the current situation. At least the P & L bears some relation to what's happening to cash.

nig
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News